Hospitals in Spain join Gamida Cell cord blood study

StemEx has orphan drug status in the US and in Europe.

The Gamida Cell-Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) joint venture announced today that five cord blood transplantations centers in Spain, three in Barcelona and two in Valencia, have joined the ExCell study.

The new clinical sites include are Hospital Clínic of Barcelona, Hospital Clínico Universitario de Valencia, Hospital de la Santa Creu i Sant Pau, Hospital Germans Trias i Pujol, and Hospital Universitario La Fe.

The trial is assessing the safety and efficacy of StemEx as a treatment for hematological malignancies, including leukemia and lymphoma, in a single arm, global, pivotal marketing authorization trial. StemEx is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells from the same unit.

StemEx is being developed by a Joint Venture of Gamida Cell and Teva. It has been granted orphan drug status in the US and in Europe.

Published by Globes [online], Israel business news - - on June 4, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018